EASL Studio Podcast: JHEP Live: New and promising drugs for NASH on the horizon

EASL Podcasts - A podcast by European Association for the Study of the Liver

Try Bookbeat 60! days for free, click here

Try Bookbeat 60! days for free, click here

Enjoy a whole world of audiobooks and e-books, everything from new releases to the classics

 Sponsored

Non-alcoholic steatohepatitis (NASH) is rapidly emerging as a leading cause of chronic liver disease, presenting significant challenge due to the limited treatment options available.This EASL Studio JHEP Live aims to explore novel and promising treatments currently being evaluated for the treatment of NASH. In particular:ARO-HSD, an HSD17β13 inhibitor.PXL065 under evaluation in the DESTINY-1 trial.The investigation of an FXR agonist in fibrotic NASH as part of the LIVIFY trial.FacultyProf. Vl...